Takeda commends the signing of the first Drugs for Rare Disease Bilateral Agreement in Canada. The bilateral agreement between British Columbia and the Federal government is an important step towards improving the patient journey for the 1 in 12 Canadians living with rare disease. This agreement involves a $194 million investment over three years to improve access to medications for rare diseases, early diagnosis, and screening. As a committed partner, Takeda looks forward to seeing bilateral agreements signed with all provinces and territories to ensure that all Canadians living with rare diseases benefit from the National Strategy for Drugs for Rare Disease. #raredisease #elevate4rare #cdnpoli Health Canada | Santé Canada Government of British Columbia *** Takeda se réjouit de la signature du premier accord bilatéral au Canada portant sur les médicaments pour le traitement des maladies rares qui a eu lieu aujourd’hui. L’accord bilatéral entre la Colombie-Britannique et le gouvernement fédéral constitue une étape importante vers l’amélioration du parcours des patients vivant avec une maladie rare, dont le nombre correspond à une personne sur douze au Canada. Cette entente prévoit un investissement de 194 millions de dollars sur une période de trois ans pour améliorer l’accès aux médicaments pour le traitement des maladies rares, le diagnostic précoce et le dépistage. En tant que partenaire engagé, Takeda attend avec impatience la signature d’ententes bilatérales avec toutes les provinces et tous les territoires pour veiller à ce que toutes les personnes atteintes de maladies rares au pays bénéficient de la Stratégie nationale visant les médicaments pour le traitement des maladies rares.
Today, the Governments of Canada and British Columbia announced two bilateral agreements, one to provide $194 million for drugs for rare diseases and the other for more than $232 million to support Personal Support Workers, or Health Care Assistants, as they are referred to in British Columbia. This represents a total investment of $426 million. The Government of Canada recognizes that collaborative efforts by federal, provincial, and territorial governments are needed to improve the healthcare system, which includes addressing the challenges facing the health workforce as well as improving access to affordable medications for people across the country, including those living with a rare disease. Learn more: https://ow.ly/Fv8z50SIsOT